Iovance Biotherapeutics (IOVA)
(Real Time Quote from BATS)
$10.76 USD
+0.41 (3.96%)
Updated May 21, 2024 10:44 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Iovance Biotherapeutics, Inc. [IOVA]
Reports for Purchase
Showing records 141 - 160 ( 180 total )
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Outlook: Data, BLAs and Manufacturing, Oh My; Maybe Even a Takeout? Target Upped to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Busy Week for Iovance Team as BLAs Approach This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cohort 2 Data in Checkpoint Primary Refractory Population Further Solidifies Our Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Activity and Safety-Centric Validation In-House; Awaiting Mature Data in 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Important SITC Update This Weekend; BLAs on Track by YE20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Investor Breakfast Highlights Full Steam Ahead for All Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; Building on Novel TIL Opportunities; BLA Filings for Both LN-144 and LN-145 Expected by YE20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data, FDA Visibility, and Another Targeted BLA; Priceless
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts Post CAR-T and the Rise of the Cellicon Valley Summit
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TILs Continue to Shine at ASCO; Target Increased to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Further Preparations for Commercial Success; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Shocker (Not), LN-145 Granted Breakthrough Therapy Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Melanoma Abstract Data Continue to Solidify Confidence in Pivotal Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Upcoming Inflection Points at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Important Chess Moves to Head Regulatory Agencies off at the Pass
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Iovance Officially Goes Pivotal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TIL Persistence in Patients and Continued Case for Polyclonal Approach; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2018 results; Building the Foundation for TILs in Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
What We''ve All Been Waiting For, Plus RMAT and a Chunk of Cash; Price Target Raised to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J